Abstract: This invention provides compositions consisting essentially of a polypeptide and a water-soluble polymer covalently bound thereto at the N-terminal .alpha.-carbon atom via a hydrazone or reduced hydrazone bond, or an oxime or reduced oxime bond. This invention also provides methods of making the instant compositions, pharmaceutical compositions comprising same, and kits for use in preparing same.
Abstract: This invention relates to stable non-aqueous protic formulations of peptide compounds. These stable formulations comprise peptide in non-aqueous protic solvent. They may be stored at elevated temperatures for long periods of time and are especially useful in implantable delivery devices for long term delivery of drug.
Type:
Grant
Filed:
April 16, 1999
Date of Patent:
May 23, 2000
Assignee:
Alza Corporation
Inventors:
Cynthia L. Stevenson, Sally A. Tao, Steven J. Prestrelski, James B. Eckenhoff, Jeremy C. Wright, John J. Leonard, Jr.
Abstract: This invention provides methods of modulating the immune system by administering peptides of the formula R'-Glx-Glx-Lys-R" (SEQ ID NO:1) in which Glx is Glu or Gln. In particular, this invention provides the use of peptides Thr-Ala-Glu-Glu-Lys (SEQ ID NO:34) and Thr-Pro-Glu-Glu-Lys (SEQ ID NO:33).
Type:
Grant
Filed:
October 28, 1993
Date of Patent:
May 23, 2000
Assignee:
Cytran, Inc.
Inventors:
Lawrence R. Green, Nicolay V. Sinackevich, Vadim T. Ivanov, Inessa I. Mikhalyova, Boris V. Vaskovsky, Alexander N. Mikhaltsov, Vladimir K. Khavinson, Vyacheslav G. Morozov
Abstract: The present invention relates to a novel antibacterial protein, called gloverin. Preferably, gloverin is isolated from Hyalophora moths. Alternatively, gloverin is produced by genetic engineering or by chemical synthesis.Also, the invention relates to pharmaceutical compositions comprising gloverin or pharmaceutically active fragments thereof and use of gloverin or fragments thereof as a medicament against bacterial infection. Furthermore, the invention relates to a method of treating bacterial infection comprising administration of gloverin or pharmaceutically active fragments thereof.
Type:
Grant
Filed:
January 28, 1998
Date of Patent:
May 16, 2000
Inventors:
Hans Bennich, Andreas Axen, Anette Carlsson, .ANG.ke Engstrom
Abstract: Amino acid sequences substantially identical to the C-terminal end of an .alpha.-S2 casein precursor one shown to act as growth promoters.Disclosed are sequences from Bovine .alpha.-S2 casein including the 9 C-terminal amino acids.LysValIlEProTyrValArgTyrLeu (SEQ ID NO:1)Also disclosed are foodstuffs and medicaments comprising the peptides of the invention and a method of producing same.
Type:
Grant
Filed:
July 13, 1998
Date of Patent:
May 9, 2000
Assignee:
Pepsyn Limited
Inventors:
John Arthur Smith, Mark Charles Wilkinson, Qing-Ming Liu
Abstract: An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) ##STR1## and compounds of the formula (VI) ##STR2## can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.
Type:
Grant
Filed:
October 24, 1996
Date of Patent:
May 2, 2000
Assignee:
Senju Pharmaceutical Co., Ltd.
Inventors:
Chiho Fukiage, Mitsuyoshi Azuma, Jun Inoue, Masayuki Nakamura, Yuka Yoshida
Abstract: The invention relates to a method of administering a fatty acid-acylated insulin or insulin analog by inhalation, a method for treating diabetes by administering a fatty acid-acylated insulin or insulin analog by inhalation, and a method for treating hyperglycemia by administering a fatty acid-acylated insulin or insulin analog by inhalation.
Type:
Grant
Filed:
October 29, 1998
Date of Patent:
April 18, 2000
Assignee:
Eli Lilly and Company
Inventors:
Benjamin Lee Hughes, Ronald Keith Wolff
Abstract: The invention provides compounds for use in the treatment of allergic diseases including juvenile asthma and eczema. The compounds can inhibit IgE mediated reaction to major environmental and occupational allergens and can also have a prophylactic effect against allergic disease by preventing allergic sensitization to environmental and occupational allergens when administered to at-risk individuals (e.g., those at genetic risk of asthma and those exposed to occupational allergens in the workplace). The compounds are also useful for inactivation or attenuation of the allergenicity of allergens in situ. The invention provides compounds and ligands per se, pharmaceutical compositions containing the compounds, processes for producing the compounds and pharmaceutical compositions, and methods for using the compounds and compositions in treatment or prophylaxis of IgE mediated allergic diseases and in inactivation or attenuation of allergens in situ.
Type:
Grant
Filed:
February 26, 1998
Date of Patent:
March 7, 2000
Assignee:
Peptide Therapeutics Limited
Inventors:
Tony Johnson, Terrance Hart, Peter Laing, Farouk Shakib, Martin Quibell
Abstract: Cyclic peptides and compositions comprising such cyclic peptides are provided. The cyclic peptides comprise a cadherin cell adhesion recognition sequence HAV. Methods for using such peptides and compositions for modulating cadherin-mediated cell adhesion in a variety of contexts are also provided.
Abstract: An automated peptide design and synthesis method is provided, wherein peptides are synthesized on interior, inward facing surfaces of reservoirs formed in a solvent resistant substrate. Novel substrates, as well as novel solutions for storing protected carboxyl terminal amino acids, are also provided.
Abstract: Methods of adjusting or maintaining the intracellular levels of glutathione of a subject are provided. The subject is treated by administering an effective amount of an acetyl derivative of glutathione.
Abstract: Compounds related to BNP have reduced binding affinity for the natriuretic peptide receptor-C but possess improved or equivalent affinity to the wild type BNP for natriuretic peptide receptor-A. The BNP related compounds are suitable for use in the treatment or prophylaxis of various pathological conditions associated with water or electrolyte imbalance.
Abstract: Controlled release compositions and methods for inducing pseudopregnancy in gilts and sows are disclosed. In the preferred embodiment, the formulation includes polylactide microspheres releasing estradiol 17.beta. at physiologically useful levels over a period of time between five and thirty days. Following induction of pseudopregnancy, the pseudopregnancy can be terminated and estrus induced by administration of a compound such as PGF2.alpha.. The advantages of inducing pseudopregnancy followed by induction of estrus are that the breeding patterns of large numbers of gilts and sows can be controlled.
Abstract: This invention discloses a method for chemically modifying a pulmonary surfactant protein or polypeptides with various fatty acids. These conjugates are useful in preparing formulations for the treatment of respiratory disease.
Type:
Grant
Filed:
December 10, 1991
Date of Patent:
February 8, 2000
Assignee:
Abbott Laboratories
Inventors:
Virender Kumar Sarin, Darryl Robin Absolom, Shanker Lal Gupta
Abstract: The invention relates to a penetration-resistant composition comprising at least one layer in which fibers having a tenacity of at least 900 MPa (7 g/denier) according to ASTM D-885 are present and which layer is bonded to a polymeric continuum having a flexural modulus of 42 to 1,000 MPa according to ASTM D-790, a tensile strength at break of at least 10 MPa according to ASTM D-638 and an elongation to break of at least 100% according to ASTM D-638.The invention furthermore relates to armour comprising multiple layers of such a composition and to a process for manufacturing such a composition.
Type:
Grant
Filed:
November 19, 1996
Date of Patent:
February 8, 2000
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Friedrich V. Pfister, Antoine Schelling
Abstract: This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
Abstract: This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.
Abstract: The present invention describes compositions of biologically active surfactant proteins SP-B and SP-C of high purity and high-yield methods for isolating SP-B and SP-C.
Type:
Grant
Filed:
April 25, 1997
Date of Patent:
February 1, 2000
Assignee:
ONY, Inc.
Inventors:
Edmund A. Egan, Lynn M. Hiavaty, Bruce A. Holm
Abstract: Methods are provided of treating the symptoms of neurological disorders including those selected from the group consisting of autism, multiple sclerosis and enuresis by administering to a patient diagnosed with the neurological disorder a composition containing an effective amount of secretin.